rs121907941
Variant summary
Our verdict is Likely pathogenic. The variant received 8 ACMG points: 8P and 0B. PM2_SupportingPM3_StrongPS3_SupportingPP4_Moderate
This summary comes from the ClinGen Evidence Repository: The NM_000152.5:c.1585_1586delinsGT variant in GAA is predicted to cause substitution of serine by valine at amino acid 529 (p.Ser529Val). At least 5 patients with this variant had documented GAA deficiency with <10% of normal mean control level of GAA activity in leukocytes, lymphocytes, muscle samples or were noted to have deficient GAA activity but results were not provided(PMIDs: 11053688, 17805474, 21984055) (PP4_Moderate). Of those individuals, 2 were compound heterozygous for the variant and a pathogenic variant as classified by the ClinGen Lysosomal Diseases VCEP (PMIDs 17805474, 11053688). Three individuals were homozygous for the variant (PMIDs: 21984055, 11053688) (PM3_Strong). This variant is absent in gnomAD v4.1.0. (PM2_Supporting). This variant results in 14.1% GAA activity when expressed in COS-1 cells by Tsunoda et al, 1996 (PMID 8834250), 10% GAA activity when expressed in SV40 immortalized fibroblasts (TR4912) by Tsujino S et al, 2000 (PMID 11053688), 9.0% wild-type activity in transiently transfected HEK293T cells by Shimada Y et al, 2014 (PMID 25256446), and 14% in transfected COS-7 cells by Flanagan et al, 2009 (PMID:19862843) (PS3_Supporting). There is a ClinVar entry for this variant (Variation ID: 4026, 0 star review status). In summary, this variant meets the criteria to be classified as Likely Pathogenic for Pompe disease based on the GAA-specific ACMG/AMP criteria applied, as specified by the ClinGen Lysosomal Diseases Variant Curation Expert panel (Specifications Version 2.0): PM3_Strong, PP4_Moderate, PM2_Supporting, PS3_Supporting.(Classification approved by the ClinGen Lysosomal Diseases Variant Curation Expert Panel on June 17, 2025) LINK:https://erepo.genome.network/evrepo/ui/classification/CA116604/MONDO:0009290/010
Frequency
Consequence
NM_000152.5 missense
Scores
Clinical Significance
Conservation
Publications
- glycogen storage disease IIInheritance: AR Classification: DEFINITIVE, STRONG Submitted by: Genomics England PanelApp, Laboratory for Molecular Medicine, Labcorp Genetics (formerly Invitae), PanelApp Australia, ClinGen, G2P
- glycogen storage disease due to acid maltase deficiency, infantile onsetInheritance: AR Classification: SUPPORTIVE Submitted by: Orphanet
- glycogen storage disease due to acid maltase deficiency, late-onsetInheritance: AR Classification: SUPPORTIVE Submitted by: Orphanet
Genome browser will be placed here
ACMG classification
Our verdict: Likely_pathogenic. The variant received 8 ACMG points.
Transcripts
RefSeq
Ensembl
Frequencies
GnomAD3 genomes Cov.: 33
GnomAD4 genome Cov.: 33
ClinVar
Submissions by phenotype
GLYCOGEN STORAGE DISEASE II, ADULT FORM Pathogenic:1
- -
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at